Parkinson disease, Multiple system atrophy-Parkinsonian type, Progressive supranuclear palsy
Conditions
Interventions
Progressive Supranuclear Palsy Group:None
Parkinson Disease 's Group:None
Healthy Control Group:None
Multiple system atrophy - parkinsonian type Group:None
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Study Subjects: All Parkinson's Disease (PD) cases met the criteria for "clinically confirmed" idiopathic Parkinson's Disease as specified in the Chinese Diagnostic Criteria for Parkinson's Disease (2016 Edition); all Multiple System Atrophy-Parkinsonism type (MSA-P) cases conformed to the definition of "clinically probable" Multiple System Atrophy in the Chinese Expert Consensus on Diagnostic Criteria for Multiple System Atrophy (2022), with parkinsonism as the main manifestation; all Progressive Supranuclear Palsy (PSP) cases satisfied the criteria for "clinically possible, probable, or definite" Progressive Supranuclear Palsy outlined in the Chinese Clinical Diagnostic Criteria for Progressive Supranuclear Palsy; 2. Age: >= 40 years old; 3. Source: Inpatients and outpatients of the Department of Neurology. All cases were jointly diagnosed clinically by two specialists with the professional title of Associate Chief Physician or above in the Department of Neurology. Control Group: 1. Study subjects: Healthy individuals with no clear history of neurological diseases, no positive signs found during neurological physical examination, and passed cognitive screening; 2.Age: >=40 years; 3. Source: Recruited from healthy check-up visitors at Peking University Shenzhen Hospital outpatient clinic.
Exclusion criteria
Exclusion criteria: 1. Patients who have taken antipsychotic drugs within 48 hours; 2. Patients with ophthalmic diseases such as high myopia, cataract or color blindness, or ocular diseases caused by internal diseases such as hyperthyroidism and diabetes, which affect the examination results; 3. Patients with ear and peripheral vestibular lesions; 4.Patients with neurological diseases such as stroke, encephalitis, hypoxic-ischemic encephalopathy, neuromyelitis optica spectrum disorders, epilepsy, and Alzheimer's disease that interfere with the examination results; 5. Patients with moderate to severe dementia as evaluated by cognitive assessment (MMSE <= 20 points).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Square wave jerk frequency;Accuracy;Latency;Gain;Velocity; | — |
Countries
China
Contacts
Public ContactZhijian Lin
Peking University Shenzhen Hospital
Outcome results
None listed